News
Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
Oss, NL December 11, 2025 Infant Bacterial Therapeutics AB (IBT) whose mission is to develop and commercialize pharmaceuticals for diseases affecting premature babies and BioConnection, a leading pharmaceutical Contract Manufacturing Organisation (CMO), announced the...
Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
Oss, NL December 11, 2025 Infant Bacterial Therapeutics AB (IBT) whose mission is to develop and commercialize pharmaceuticals for diseases affecting premature babies and BioConnection, a leading pharmaceutical Contract Manufacturing Organisation (CMO), announced the...
Announcement: Mireille Sanders new member of Supervisory Board at BioConnection
Oss, NL May 20, 2025 BioConnection is pleased to announce the appointment of Mireille Sanders as member of our Supervisory Board. She succeeds...
BioConnection and Prestige Biologics
We noticed that various channels shared information about the legal proceedings between BioConnection B.V. and Prestige Biologics Co. Limited: On 11...
Successful IGJ inspection completed
We are proud to share that last week BioConnection successfully completed a three-day inspection by the Healthcare and Youth Inspectorate (IGJ),...
BioConnection Receives European CMO of the Year Award 2024 in (Bio)pharmaceuticals
BioConnection is excited to share that we’ve been named the European Company of the Year in Biopharmaceutical Contract Manufacturing 2024 by Pharma...
Announcement: Richard Sewalt new Chief Commercial Officer (CCO) at BioConnection
Oss, NL September 2, 2024 We are excited to announce that Richard Sewalt has joined BioConnection as our new Chief Commercial Officer (CCO). With...
BioConnection appoints Dr. Gary M. Phillips as the new Chairman of the Supervisory Board
Oss, NL August 26, 2024 BioConnection is pleased to announce the appointment of Dr. Gary M. Phillips as the new Chairman of the Supervisory Board....